Biolase Inc (BIOL)

$0.06

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $0.05
    $0.06
    $0.06
    downward going graph

    15.0%

    Downside

    Day's Volatility :15.0%

    Upside

    0.0%

    downward going graph
  • $0.06
    $10.31
    $0.06
    downward going graph

    0.0%

    Downside

    52 Weeks Volatility :99.42%

    Upside

    99.42%

    downward going graph

Returns

PeriodBiolase IncIndex (Russel 2000)
3 Months
-58.62%
0.0%
6 Months
-57.14%
0.0%
1 Year
-98.1%
0.0%
3 Years
-100.0%
-22.3%

Highlights

Market Capitalization
2.2M
Book Value
- $0.13
Earnings Per Share (EPS)
16.18
PE Ratio
0.0
PEG Ratio
-0.22
Wall Street Target Price
1.2
Profit Margin
-41.65%
Operating Margin TTM
-27.87%
Return On Assets TTM
-27.96%
Return On Equity TTM
-736.26%
Revenue TTM
46.1M
Revenue Per Share TTM
3.32
Quarterly Revenue Growth YOY
-19.1%
Gross Profit TTM
16.5M
EBITDA
-13.2M
Diluted Eps TTM
16.18
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.44
EPS Estimate Next Year
-0.09
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Biolase Inc(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 3150.0%

Current $0.06
Target $1.95

Company Financials

FY18Y/Y Change
Revenue
46.2M
↓ 1.64%
Net Income
-21.5M
↑ 27.68%
Net Profit Margin
-46.62%
↓ 10.71%
FY19Y/Y Change
Revenue
37.8M
↓ 18.1%
Net Income
-17.9M
↓ 17.02%
Net Profit Margin
-47.24%
↓ 0.62%
FY20Y/Y Change
Revenue
22.8M
↓ 39.73%
Net Income
-16.8M
↓ 5.75%
Net Profit Margin
-73.88%
↓ 26.64%
FY21Y/Y Change
Revenue
39.2M
↑ 72.03%
Net Income
-16.2M
↓ 3.99%
Net Profit Margin
-41.23%
↑ 32.65%
FY22Y/Y Change
Revenue
48.5M
↑ 23.67%
Net Income
-28.6M
↑ 77.21%
Net Profit Margin
-59.09%
↓ 17.86%
FY23Y/Y Change
Revenue
49.2M
↑ 1.45%
Net Income
-20.6M
↓ 27.95%
Net Profit Margin
-41.97%
↑ 17.12%
Q4 FY22Q/Q Change
Revenue
14.1M
↑ 16.99%
Net Income
-9.9M
↑ 17.57%
Net Profit Margin
-70.18%
↓ 0.35%
Q1 FY23Q/Q Change
Revenue
10.5M
↓ 25.51%
Net Income
-5.8M
↓ 40.69%
Net Profit Margin
-55.88%
↑ 14.3%
Q2 FY23Q/Q Change
Revenue
14.3M
↑ 36.49%
Net Income
-4.9M
↓ 16.77%
Net Profit Margin
-34.08%
↑ 21.8%
Q3 FY23Q/Q Change
Revenue
10.9M
↓ 23.55%
Net Income
-4.6M
↓ 5.73%
Net Profit Margin
-42.02%
↓ 7.94%
Q4 FY23Q/Q Change
Revenue
13.5M
↑ 23.52%
Net Income
-5.3M
↑ 16.06%
Net Profit Margin
-39.48%
↑ 2.54%
Q1 FY24Q/Q Change
Revenue
10.1M
↓ 24.9%
Net Income
-6.5M
↑ 21.76%
Net Profit Margin
-64.01%
↓ 24.53%
FY18Y/Y Change
Total Assets
38.5M
↓ 10.39%
Total Liabilities
27.4M
↑ 99.85%
FY19Y/Y Change
Total Assets
31.8M
↓ 17.31%
Total Liabilities
31.5M
↑ 14.74%
FY20Y/Y Change
Total Assets
41.0M
↑ 28.82%
Total Liabilities
31.0M
↓ 1.5%
FY21Y/Y Change
Total Assets
55.3M
↑ 34.76%
Total Liabilities
30.1M
↓ 2.97%
FY22Y/Y Change
Total Assets
38.2M
↓ 30.93%
Total Liabilities
33.3M
↑ 10.71%
FY23Y/Y Change
Total Assets
35.1M
↓ 8.08%
Total Liabilities
35.3M
↑ 6.16%
Q4 FY22Q/Q Change
Total Assets
38.2M
↓ 10.92%
Total Liabilities
33.3M
↑ 14.79%
Q1 FY23Q/Q Change
Total Assets
41.9M
↑ 9.84%
Total Liabilities
33.8M
↑ 1.47%
Q2 FY23Q/Q Change
Total Assets
39.6M
↓ 5.51%
Total Liabilities
32.3M
↓ 4.42%
Q3 FY23Q/Q Change
Total Assets
38.7M
↓ 2.24%
Total Liabilities
32.9M
↑ 1.76%
Q4 FY23Q/Q Change
Total Assets
35.1M
↓ 9.41%
Total Liabilities
35.3M
↑ 7.57%
Q1 FY24Q/Q Change
Total Assets
34.4M
↓ 2.13%
Total Liabilities
36.3M
↑ 2.66%
FY18Y/Y Change
Operating Cash Flow
-14.1M
↓ 23.16%
Investing Cash Flow
-522.0K
↓ 30.12%
Financing Cash Flow
11.2M
↓ 48.03%
FY19Y/Y Change
Operating Cash Flow
-12.7M
↓ 9.9%
Investing Cash Flow
-207.0K
↓ 60.34%
Financing Cash Flow
10.7M
↓ 4.57%
FY20Y/Y Change
Operating Cash Flow
-12.8M
↑ 0.38%
Investing Cash Flow
-96.0K
↓ 53.62%
Financing Cash Flow
24.3M
↑ 127.12%
FY21Y/Y Change
Operating Cash Flow
-16.7M
↑ 30.6%
Investing Cash Flow
-707.0K
↑ 636.46%
Financing Cash Flow
30.0M
↑ 23.02%
Q4 FY22Q/Q Change
Operating Cash Flow
-5.6M
↓ 14.73%
Investing Cash Flow
-471.0K
↓ 82.41%
Financing Cash Flow
-32.0K
↓ 85.05%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.7M
↑ 1.36%
Investing Cash Flow
-357.0K
↓ 24.2%
Financing Cash Flow
8.5M
↓ 26715.62%
Q2 FY23Q/Q Change
Operating Cash Flow
-3.6M
↓ 37.04%
Investing Cash Flow
-357.0K
↑ 0.0%
Financing Cash Flow
4.3M
↓ 49.79%

Technicals Summary

Sell

Neutral

Buy

Biolase Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biolase Inc
Biolase Inc
-8.09%
-57.14%
-98.1%
-100.0%
-100.0%
Stryker Corporation
Stryker Corporation
12.3%
0.36%
24.19%
28.8%
65.26%
Boston Scientific Corp.
Boston Scientific Corp.
10.6%
20.32%
51.42%
80.93%
95.5%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
9.4%
-28.78%
-12.2%
-45.23%
-7.73%
Abbott Laboratories
Abbott Laboratories
3.57%
-5.84%
13.1%
-11.32%
35.19%
Medtronic Plc
Medtronic Plc
10.85%
5.57%
12.46%
-33.2%
-16.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biolase Inc
Biolase Inc
NA
0.0
-0.22
-0.44
-7.36
-0.28
NA
-0.13
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biolase Inc
Biolase Inc
Buy
$4.8M
-100.0%
NA
-41.65%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
65.26%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
95.5%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-7.73%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
35.19%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.71%
30.16
12.06%

Insights on Biolase Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 10.13M → 11.55M (in $), with an average increase of 12.3% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -6.48M → -2.79M (in $), with an average increase of 131.8% per quarter

  • Vs BSX

    In the last 1 year, Boston Scientific Corp. has given 51.4% return, outperforming this stock by 149.5%

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 180.9%

Institutional Holdings

  • Virtu Financial LLC

    0.43%

  • Millennium Management LLC

    0.35%

  • HRT FINANCIAL LLC

    0.30%

  • XTX Topco Ltd

    0.22%

  • Royal Bank of Canada

    0.15%

  • Susquehanna International Group, LLP

    0.11%

Company Information

biolase, inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment. biolase’s products are focused on better enabling clinicians to repair and restore patient’s dental conditions while reducing the pain, fear, and anxiety generally associated with dentistry. biolase is committed to elevating the standard of care in dentistry, while enabling clinicians to achieve better business returns.

Organization
Biolase Inc
Employees
157
CEO
Mr. John R. Beaver
Industry
Health Technology

Discover More

FAQs